Daré Bioscience, Inc. Forecasted to Post Q3 2023 Earnings of ($0.09) Per Share (NASDAQ:DARE)

Posted by Defense World Staff on Oct 20th, 2023

Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) – Investment analysts at Brookline Capital Management reduced their Q3 2023 earnings per share (EPS) estimates for shares of Daré Bioscience in a report released on Monday, October 16th. Brookline Capital Management analyst K. Dolliver now forecasts that the biotechnology company will earn ($0.09) per share for the quarter, down from their previous forecast of ($0.07). The consensus estimate for Daré Bioscience’s current full-year earnings is ($0.37) per share. Brookline Capital Management also issued estimates for Daré Bioscience’s Q4 2023 earnings at ($0.05) EPS.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Daré Bioscience in a research report on Friday, August 11th.

View Our Latest Stock Analysis on DARE

Daré Bioscience Price Performance

DARE opened at $0.46 on Thursday. The stock has a market cap of $40.52 million, a P/E ratio of -1.00 and a beta of 1.24. The stock’s 50 day simple moving average is $0.57 and its 200 day simple moving average is $0.80. Daré Bioscience has a 1-year low of $0.45 and a 1-year high of $1.40.

Daré Bioscience (NASDAQ:DARE – Get Free Report) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.10).

Institutional Investors Weigh In On Daré Bioscience

A number of hedge funds have recently made changes to their positions in DARE. Renaissance Technologies LLC raised its holdings in Daré Bioscience by 26.3% during the second quarter. Renaissance Technologies LLC now owns 718,821 shares of the biotechnology company’s stock worth $654,000 after purchasing an additional 149,762 shares in the last quarter. Jane Street Group LLC grew its position in Daré Bioscience by 240.0% in the first quarter. Jane Street Group LLC now owns 75,342 shares of the biotechnology company’s stock worth $78,000 after buying an additional 53,180 shares during the last quarter. State Street Corp grew its position in Daré Bioscience by 9.6% in the first quarter. State Street Corp now owns 247,710 shares of the biotechnology company’s stock worth $258,000 after buying an additional 21,600 shares during the last quarter. Virtu Financial LLC grew its position in Daré Bioscience by 13.5% in the fourth quarter. Virtu Financial LLC now owns 77,469 shares of the biotechnology company’s stock worth $64,000 after buying an additional 9,227 shares during the last quarter. Finally, Morgan Stanley grew its position in Daré Bioscience by 283.4% in the fourth quarter. Morgan Stanley now owns 67,646 shares of the biotechnology company’s stock worth $56,000 after buying an additional 50,000 shares during the last quarter. Institutional investors own 7.41% of the company’s stock.

Daré Bioscience Company Profile

(Get Free Report)

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health.